Key result
MuRF1 and MAFbx/atrogin-1 expression increases under atrophy-inducing conditions to serve as critical muscle atrophy markers.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
MuRF1/MAFbx expression validates atrophy markers in research; leaves open their full roles and therapeutic targeting.
Muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx)/atrogin-1 were identified more than 10 years ago as two muscle-specific E3 ubiquitin ligases that are increased transcriptionally in skeletal muscle under atrophy-inducing conditions, making them excellent markers of muscle atrophy. In the past 10 years much has been published about MuRF1 and MAFbx with respect to their mRNA expression patterns under atrophy-inducing conditions, their transcriptional regulation, and their putative substrates. However, much remains to be learned about the physiological role of both genes in the regulation of mass and other cellular functions in striated muscle. Although both MuRF1 and MAFbx are enriched in skeletal, cardiac, and smooth muscle, this review will focus on the current understanding of MuRF1 and MAFbx in skeletal muscle, highlighting the critical questions that remain to be answered.
No takes yet. Share an insight, caveat, or question.
Bodine et al. (2014) studied this question. MuRF1 and MAFbx/atrogin-1 are critical markers of muscle atrophy in skeletal muscle, with increased expression under atrophy-inducing conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: